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Background: There is strong evidence for a bidirectional association between 
depression and obesity. Several biological, psychological, and behavior-related factors 
may influence this complex association. Clinical impression and preliminary evidence 
suggest that patients with a diagnosis of major depressive disorder may endorse very 
different depressive symptom patterns depending on their body weight status. Until now, 
little is known about potential differences in depressive symptoms in relation to body 
weight status.
Objective: The aim of this analysis is the investigation of potential differences in depressive 
symptom clusters (mood symptoms, somatic/vegetative symptoms, and cognitive 
symptoms) in relation to body weight status.
Methods: Cross-sectional baseline data were derived from two large European multicenter 
studies: the MooDFOOD Trial and the NESDA cohort study, including persons with 
overweight and obesity and normal weight reporting subthreshold depressive symptoms 
(assessment via Inventory of Depressive Symptomatology Self-Report, IDS-SR30). 
Different measures for body weight status [waist-to-hip ratio (WHR) and body mass index 
(BMI)] were examined. Propensity score matching was performed and multiple linear 
regression analyses were conducted.
Results: A total of n = 504 individuals (73.0% women) were analyzed. Results show 
that more somatic/vegetative depressive symptoms, such as pain, change in appetite 
and weight, gastrointestinal symptoms, and arousal-related symptoms, were significantly 
associated with both a higher BMI and higher WHR, respectively. In addition, being 
male and older age were significantly associated with higher WHR. Mood and cognitive 
Frontiers in Psychiatry | www.frontiersin.org
ORiginaL RESEaRCh
doi: 10.3389/fpsyt.2019.00858
published: 21 November 2019
November 2019 | Volume 10 | Article 858
Depressive Symptoms and Body Weight StatusBaldofski et al.
2
inTRODUCTiOn
Major depressive disorder (MDD) is among the most prevalent 
and disabling mental disorders, one of the leading causes of 
disability worldwide, and a major contributor to the overall 
global burden of disease (1). One of the most prevalent somatic 
comorbidities of MDD is obesity (2, 3). Several studies have 
provided evidence for a bidirectional link between depression 
and obesity in a way that the presence of one is increasing the risk 
of developing the other (3–6). Further, as stated by Milaneschi et 
al. (3), there is strong reason to believe that these conditions are 
interconnected through a vicious, mutually reinforcing cycle of 
adverse physiological adaptations.
Several factors, such as biological, psychological, and behavior-
related ones, may influence this complex association between 
depression and obesity (e.g., 7, 9–12). Moreover, depression and 
obesity are two major risk factors of negative health outcomes 
(10, 13, 14).
The inter-individual heterogeneity of depressive symptoms in 
different patients with MDD grants to a greater variability in its 
association with obesity. This association seems to be stronger 
in certain subgroups of patients (3, 6, 15, 16); for example, 
the association between depression and obesity is found to be 
stronger for abdominal obesity, and in some studies and certain 
populations, it was found to be inverse or even absent (17–19). 
Several (e.g., genetic and inflammatory) factors and mechanisms 
are being discussed in the international literature to date (3, 10, 
20–22). Genetic factors influence likewise depression and obesity, 
with additive effects explaining the phenotypic variation for both 
depression and body mass index (BMI) (3, 23, 24). To sum up, there 
is emerging evidence that the relationship between depression and 
obesity has its origins in partially overlapping genetic bases (3).
The clinical impression also supports the hypothesis that 
patients with the same MDD diagnosis may endorse very different 
symptom patterns depending on their body weight status (3). For 
example, obesity seems to be associated with fatigue in the sense 
of tiredness (lack of drive and sleepiness), which may result from 
somatic reactions to the condition of obesity, whereas typical 
depression is associated with inhibition of drive and long sleep 
latencies (25–27).
In the past decades, quite some efforts have been made to 
determine and establish different depressive symptom patterns 
or clusters and examine their influence on various health-related 
outcomes. In most of these studies, depressive symptom patterns 
or clusters were distinguished as follows: a) two symptom clusters: 
cognitive-affective (e.g., pessimism, guilt, and self-dislike) and 
somatic-affective (e.g., insomnia, fatigue, and work difficulty) 
depressive symptoms (28, 29) or b) three symptom clusters: 
cognition/mood, anxiety/arousal, and vegetative symptoms (or 
sleep) (30, 31). However, other distinctions were also proposed, 
such as a differentiation between atypical and melancholic 
depressive subtypes (32–34).
As mentioned above, a growing body of evidence indicates 
that abdominal obesity is a more important risk factor of MDD 
than general obesity (35). It seems to be the key mediator 
in the relationship between obesity and depression (36). 
Results indicate a positive association between abdominal 
fat distribution [measured by waist-to-hip ratio (WHR)] and 
prevalence of depression, and further that abdominal obesity 
is a risk factor of depression independently of general obesity 
(measured by BMI). Nevertheless, some epidemiological studies 
report no association between unfavorable waist circumference 
and mental disorders (in particular depression) (17). Considering 
these differential associations, it seems beneficial to take into 
account different measures for body weight status, not only 
BMI (37).
However, only a few studies have addressed anthropometric 
measures in relation to different depressive symptoms so far 
(38), with equivocal results: one study reported that BMI was 
associated with both cognitive-affective and somatic-affective 
depressive symptom patterns of the Beck Depression Inventory 
I (BDI-I), whereas waist circumference and WHR were only 
associated with somatic-affective, but not cognitive-affective 
symptoms (39). Another study reported as a secondary result that 
BMI at baseline was significantly correlated with improvement 
in neurovegetative and cognitive symptoms of depression (2). It 
has also been shown in a population-based study that only the 
somatic, not the cognitive-affective, symptoms of depression 
are positively associated with anthropometric measures of 
obesity (35).
The aim of this study is the investigation of self-rated 
depressive symptoms (assessed with the Inventory of 
Depressive Symptomatology Self Report, IDS-SR30 clusters: 
mood symptoms, somatic/vegetative symptoms, and cognitive 
depressive symptoms did not yield significant associations for both body weight 
status measures.
Conclusions: Somatic/vegetative symptoms and not mood and cognitive symptoms of 
depression are associated with body weight status. Thus, the results support previous 
findings of heterogeneous depressive symptoms in relation to body weight status. In 
addition to BMI, other body weight status measures for obesity should be taken into 
account in future studies.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02529423.
Keywords: depression, depressive symptoms, obesity, overweight, body mass index
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symptoms) in relation to body weight status in persons with 
overweight and obesity and normal-weight individuals reporting 
subthreshold depressive symptoms. Different measures for body 
weight status (WHR and BMI) will be examined.
METhODS
Study Design
This publication includes baseline data from two large European 
multicenter studies: the MooDFOOD Trial (“Multi-country 
cOllaborative project on the role of Diet, Food-related behavior, 
and Obesity in the prevention of Depression”) and the NESDA 
Study (“The Netherlands Study of Depression and Anxiety”), 
respectively.
The MooDFOOD Trial for the prevention of depression in 
individuals with overweight and obesity reporting subclinical 
depressive symptoms is a 2 × 2 factorial randomized controlled 
trial. It was carried out between July 2015 and October 2017 in 
four European countries (Germany, Spain, United Kingdom, and 
the Netherlands). For full details of trial design and protocol see 
Roca et al. (40), and for primary outcome results see Bot et al. 
(41). The trial was approved by the Human Research Ethics 
Boards of all four study sites. All participants provided written 
informed consent prior to participation.
The NESDA Study is an ongoing multicenter, longitudinal, 
naturalistic cohort study examining the 9-year course and 
consequences of depressive and anxiety disorders (for details 
of study design and protocol, see 42). Baseline assessments of 
NESDA took place between 2004 and 2007. The study includes 
persons with a current or lifetime diagnosis of depression and/
or anxiety disorder, persons being at risk for these disorders 
because of a family history or subthreshold depressive or anxiety 
symptoms, and healthy controls, respectively. Ethics approval 
was provided by the local review boards of all study sites and 
written informed consent was obtained from all participants 
prior to participation.
For this publication, baseline data from both the MooDFOOD 
Trial (total N = 1,025) and the NESDA Study (total N = 2,981) 
were combined to provide a sample with a wide range of body 
weight status. To this end, only the data of normal-weight 
participants from the NESDA Study were used to provide a 
matching sample to the MooDFOOD data of individuals with 
overweight and obesity (see below for details on propensity score 
matching procedure).
Recruitment and Eligibility Criteria
Participants for the MooDFOOD Trial were recruited from 
the general population via websites, advertisements, and press 
releases as well as via other studies conducted at the study sites 
and mailings to registered subjects in the general practice setting 
or in city registers. Inclusion criteria were age 18-75 years, BMI in 
the range of 25–40 kg/m2, and subclinical depressive symptoms 
as operationalized by a Patient Health Questionnaire (PHQ-9) 
score of ≥5 (43). Main exclusion criteria included a current 
(including the past 6 months) MDD episode according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; 
(44), as assessed by the Mini-International Neuropsychiatric 
Interview (MINI 5.0; 45), current use of antidepressants, current 
eating disorder or a severe life-threatening physical disease (e.g., 
cancer), and a history of psychosis, bipolar disorder, substance 
dependence, or another severe psychiatric disorder (40). All 
eligible participants were invited for a baseline interview, 
physical measurements, and blood sampling conducted by 
trained research assistants/nurses and the completion of self-
report questionnaires. Follow-up assessments took place at 3, 6, 
and 12 months.
Participants for the NESDA Study were recruited from 
community samples, primary care practices, and mental 
health organizations, in order to represent diverse settings and 
developmental stages of psychopathology. Participants aged 
18–65 years were included in the study. Further inclusion criteria 
were a current (including the past 6 months) or lifetime diagnosis 
of depression (minor or major depression, dysthymia) or anxiety 
disorders according to the DSM-IV, as assessed by the Composite 
International Diagnostic Interview (CIDI, WHO version 2.1; 46). 
In addition, persons with a family history of depression or anxiety 
disorders and with subclinical depressive or anxiety symptoms 
were included, as well as healthy controls without any depressive 
or anxiety symptoms. Main exclusion criteria were psychosis, 
obsessive compulsive disorder, bipolar disorder, severe addiction, 
and a history of stroke (42). Eligible participants were invited for 
a baseline assessment including clinical interviews and physical 
measurements conducted by trained research assistants and the 
completion of self-report questionnaires. Follow-up assessments 
took place every 2 years after baseline and are currently ongoing.
Propensity Score Matching 
and Study Sample
The baseline data of the MooDFOOD Trial included N = 1,025 
participants in total. To match these data with the data of the 
NESDA Study, n = 35 participants had to be excluded from the 
dataset [n = 14 with normal body weight and n = 21 with history 
of stroke (exclusion criterion in the NESDA sample)], resulting 
in a dataset of n = 990 participants from the MooDFOOD Trial.
Baseline data of the NESDA Study included N = 2,981 
participants. Of these, n = 2,544 had to be excluded during 
data preparation for the following reasons: n = 1,481 not 
normal body weight, n = 540 with current MDD (as this was an 
exclusion criterion in MooDFOOD), n = 113 with antidepressant 
medication, n = 94 with alcohol dependence, and n = 316 with 
anxiety disorders. Thus, the final selected sample out of the 
NESDA Study comprised n = 437.
To obtain a final sample with a wide range of body weight 
status, including persons with overweight and obesity from the 
MooDFOOD Trial as well as normal-weight persons from the 
NESDA Study, propensity score matching was performed (47). 
Based on their propensity scores calculated by logistic regression 
(nearest neighbor matching algorithm, caliper 0.2), samples 
were matched according to sex, age, and distribution of IDS 
scores. The final matched sample comprised n = 504 participants 
(n = 252 from the MooDFOOD Trial and n = 252 from the 
NESDA Study).
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Measures
Depressive Symptoms. In both the MooDFOOD Trial and 
the NESDA Study, the 30-item Inventory of Depressive 
Symptomatology Self-Report (IDS-SR30; 30, 48) was 
administered to assess depressive symptoms (0 = no problems 
to 3 = severe problems). The two separate items on weight loss 
and weight gain were recoded into a single variable. The two 
items on increased and decreased appetite, respectively, were 
recoded similarly, resulting in a total of 28 items for the IDS (9, 
31). A total sum score was calculated (range, 0–84), with higher 
scores indicating higher levels of depressive symptomatology. 
In accordance with previous studies, individual symptoms were 
categorized into three depressive symptom clusters (deductively 
defined): mood symptoms, cognitive symptoms, and somatic/
vegetative symptoms (9, 49, 50). A sum score was calculated for 
each cluster (mood symptoms: 10 items, range 0–30; cognitive 
symptoms: 4 items, range 0–12; somatic/vegetative symptoms: 14 
items, range 0–42; see Supplementary Table).
Body Weight Status. Body weight, height, and waist and 
hip circumference were measured objectively according to 
written, standardized protocols (identical measurement in both 
subsamples). BMI (in kilograms per square meter) and WHR (waist 
circumference divided by hip circumference) were calculated.
Presence of Lifetime MDD. The presence of a lifetime diagnosis 
of MDD according to the DSM-IV (44) was assessed in all study 
participants using clinical interviews, specifically the MINI 5.0 
(45) in the MooDFOOD Trial and the CIDI [WHO version 2.1 
(46)] in the NESDA Study.
Demographic Variables. Sex and age were assessed in the 
baseline interview in both, MooDFOOD and NESDA.
All applied interview and questionnaire instruments 
demonstrated good reliability and validity (51–53). The IDS 
showed good internal consistency with Cronbach’s α = .80.
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics 
version 24.0. Differences in sample characteristics between 
participants from MooDFOOD and NESDA, respectively, were 
examined using general linear model analyses for continuous 
variables (age, BMI, WHR, and IDS scores) and χ2 tests for 
categorical variables (sex and prevalence of lifetime MDD). To 
analyze the relationship between depressive symptoms and body 
weight status, two separate multiple linear regression analyses were 
computed with the anthropometric measure (BMI and WHR) as 
the continuous dependent variable and the depressive symptoms 
(clusters: mood symptoms, cognitive symptoms, and somatic/
vegetative symptoms) and sociodemographic variables (sex and age) 
as the independent variables. Tests for assumption of collinearity 
of the independent variables showed that multicollinearity was not 
a concern. The independent variables were entered into the models 
simultaneously. Effect size of prediction was evaluated according 
to Cohen (54), R2: small, .01; medium, .09; large, .25. A two-tailed 
α = 0.05 was applied to all statistical testing.
RESULTS
Sample Characteristics
Participants from MooDFOOD (n = 252) and NESDA (n = 
252), respectively, did not differ regarding sex, age, prevalence 
of lifetime MDD, IDS total scores, and IDS symptom clusters (all 
p > .05; see Table 1). As expected, participants from MooDFOOD 
showed significantly higher BMI and WHR than participants 
from NESDA (all p < .05).
The total sample comprised n = 504 individuals (73.0% 
women) with a mean age of M = 41.93 years (SD = 13.61), a mean 
BMI of M = 26.62 kg/m2 (SD = 5.33, range = 18.56–42.10 kg/m2), 
and a mean WHR of M = 0.86 (SD = 0.09, range = 0.66–1.12; see 
Table 1). Criteria for a lifetime MDD diagnosis were met by n = 
150 (29.9%). Based on IDS cutoff scores for clinical severity of 
depressive symptoms, no values fell in the categories of severe 
or very severe depressive symptoms. Of the total sample, n  = 
292 (58%) participants had no or low severity of depressive 
symptoms, n = 175 (35%) had mild severity, and n = 37 (7%) 
displayed moderately severe depressive symptoms, respectively.
TaBLE 1 | Sample characteristics for the MooDFOOD and NESDA subsamples and the total matched sample.
Total sample (n = 504) MooDFOOD (n = 252) nESDa (n = 252) Test p
Sex (N female, %) 368 (73.0) 185 (73.4) 183 (72.6) χ2(1) = 0.04 .841
Lifetime MDD (N, %) 150 (29.9) 76 (30.4) 74 (29.4) χ2(1) = 0.06 .800
M (SD) M (SD) M (SD) F(1, 502)
Age 41.93 (13.61) 42.52 (12.85) 41.35 (14.33) 0.93 .335
Body mass index (kg/m2) 26.62 (5.33) 31.04 (3.86) 22.19 (1.66) 1,117.92 <.001
Waist-to-hip ratio 0.86 (0.09) 0.89 (0.09) 0.82 (0.07) 92.42 <.001
IDS total score 13.47 (7.52) 13.69 (7.52) 13.25 (7.53) 0.44 .508
 Mood symptoms 4.11 (3.41) 4.13 (3.41) 4.10 (3.41) 0.01 .927
 Cognitive symptoms 1.66 (1.67) 1.64 (1.57) 1.69 (1.78) 0.12 .730
 Somatic/vegetative symptoms 7.67 (4.03) 7.92 (4.02) 7.41 (4.03) 2.07 .151
Using propensity score matching, samples from the MooDFOOD Trial and the NESDA Study were matched according to sex, age, and distribution of IDS sum scores. 
Tests for group differences refer to differences between the MooDFOOD and NESDA subsamples, respectively.
M, mean; SD, standard deviation; MDD, major depressive disorder; IDS, Inventory of Depressive Symptomatology Self-Report.
Bold type p < .05.
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Multiple Linear Regression analyses
Two separate multiple linear regression analyses were calculated to 
predict BMI and WHR, respectively, based on sociodemographic 
variables and depressive symptom clusters. The first analysis with 
BMI as the outcome variable did not yield a significant regression 
equation: F(5, 498) = 2.01, p = .076, R2 = .02, adjusted R2 = .01; see 
Table 2 and Supplementary Figure). While sociodemographic 
variables as well as mood and cognitive symptoms were not 
significantly associated with BMI (all p > .05), results showed that 
the somatic/vegetative symptom cluster had a significant effect 
(p  = .013). More somatic/vegetative symptoms were associated 
with a higher BMI.
Results of the second analysis with WHR as the outcome 
variable indicated that there was a collective significant 
association of the independent variables: F(5, 496) = 50.11, p < 
.001, R2 = .34, adjusted R2 = .33; see Table 2 and Supplementary 
Figure). Examination of the individual variables showed that 
sex, age, and somatic/vegetative symptoms yielded significant 
effects in the model (all p < .01). Being male, older age, and 
more somatic/vegetative symptoms were associated with a 
higher WHR.
In both models, standardized regression coefficients (beta) for 
somatic/vegetative symptoms were larger than those for mood 
and cognitive symptoms, respectively (see Table 2).
DiSCUSSiOn
The aim of this study was to investigate the relationship between 
depressive symptom clusters (mood symptoms, somatic/
vegetative symptoms, and cognitive symptoms) in relation to 
body weight status, measured by BMI and WHR, in individuals 
with subthreshold depressive symptoms. Using a sample 
comprising two large European multicenter studies, the current 
study is, to our knowledge, the first to address this question.
Results showed that the significant regression model with 
WHR as the outcome variable yielded a reasonably high model fit, 
explaining 33% of the variance. It revealed that being male, being 
of older age, and reporting more depressive symptoms of the 
somatic/vegetative symptom cluster were significantly associated 
with higher WHR. Mood and cognitive symptoms did not show 
any significant contribution. To sum up, age, sex, and somatic/
vegetative symptoms, but not mood or cognitive symptoms, were 
significantly associated with WHR. This finding is in line with 
previous research indicating that the somatic/affective symptoms 
of depression rather than the cognitive/affective ones are 
consistently related to anthropometric measures of obesity (35).
The regression model with BMI as the outcome variable 
did not reach statistical significance overall, meaning that the 
majority of the variables did not contribute to BMI. Nevertheless, 
the factor somatic/vegetative symptoms yielded a significant 
effect, which points towards the fact that this factor is associated 
with BMI, but the others do not.
Overall, the results of this study provide further evidence 
that somatic/vegetative symptoms rather than mood/cognitive 
symptoms of depression are associated with WHR, and 
potentially of BMI as well. Somatic/vegetative symptoms include 
pain, change in appetite and body weight, gastrointestinal, and 
several arousal-related symptoms (sleep and energy level) (see 
Supplementary Table). The latter are depressive symptoms that 
are mainly manifested in the somatic area, which might overlap 
or coincide with complaints and symptoms accompanying 
or resulting from overweight or obesity and co-occurring 
somatic conditions.
Moreover and also in line with the international literature, the 
results suggest that future research should take different body 
weight status measures (such as WHR) for obesity into account, 
not only BMI, as other measure index abdominal obesity, which 
is proposed to be the key factor in the obesity–depression 
relationship (35, 36).
The current study has important strengths. It included a 
large, multicenter, multi-country, and propensity score-matched 
sample and further used standardized assessment instruments. 
However, there are also some limitations. First, the results might 
not be generalizable to the full spectrum of depressive disorders 
and specifically to individuals currently suffering from MDD, as 
the study population comprised individuals with subthreshold 
symptoms of depression, but indeed 30% with a lifetime MDD 
diagnosis. Nevertheless, the full range of body weight state was 
included in the analysis. Due to the cross-sectional design, 
causal inferences are not possible and not all potentially relevant 
control variables (e.g. physical activity) could be included into 
the analysis. The depressive symptoms being analyzed in this 
study are administered via self-report measures, which might 
be biased by social desirability and other factors. Also, self-
report instruments and clinician-rated scales differ regarding 
content and weighting of different symptom dimensions. Also, 
the potential role of certain medical comorbidities regarding this 
association is not addressed within this analysis.
In conclusion, the present study provides further evidence 
that there is heterogeneity in depressive symptoms in relation to 
body weight status, especially as assessed by the WHR. Future 
studies could investigate the longitudinal course of different 
depressive symptom clusters and their differential associations 
with body weight status in the long term. Treatment strategies 
TaBLE 2 | Linear regression analyses of depressive symptom clusters and 
weight status (n = 504; matched sample from MooDFOOD and NESDA)
Total sample (N = 504)
β B SE B p
Body mass index
 Sex 0.04 -0.46 0.54 .369
 Age 0.07 0.03 0.02 .117
 Mood symptoms -0.03 -0.04 0.10 .650
 Cognitive symptoms -0.04 -0.13 0.18 .476
 Somatic/vegetative symptoms 0.13 0.18 0.07 .013
Waist-to-hip ratio
 Sex -0.50 -0.10 0.01 <.001
 Age 0.30 0.00 0.00 <.001
 Mood symptoms -0.05 0.00 0.00 .293
 Cognitive symptoms -0.02 0.00 0.00 .704
 Somatic/vegetative symptoms 0.12 0.00 0.00 .006
Bold type p < .05.
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of both depression and obesity should take the present results 
into account, e.g., by adapting and targeting interventions to 
the presented (heterogeneous) symptoms displayed by the 
individual patient.
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